Comparative Pharmacology
Head-to-head clinical analysis: ANCOBON versus ORAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCOBON versus ORAVIG.
ANCOBON vs ORAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Miconazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
ORAVIG (miconazole) 50 mg buccal tablet applied once daily to the upper gum region (canine fossa) for 14 consecutive days. The tablet is placed with the rounded side against the gum and held in place for 30 seconds to ensure adhesion.
None Documented
None Documented
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (CrCl < 20 mL/min). Half-life correlates with creatinine clearance.
Terminal elimination half-life is approximately 24 hours, supporting once-daily buccal administration for sustained local oropharyngeal concentrations.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Primarily fecal (approximately 52%) with 39% of the dose recovered in urine; less than 0.5% of the dose is excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal